Clinical trial Recruiting at 1 site Observational Ages Any age to 100 Days

Early genetic screening for critical illnesses in newborns

Official title: Study on Early Genetic Screening and Precise Strategy of Neonatal Critical Illness

Run by Children's Hospital of Fudan University · NCT04905537 · Data updated 2026-11-12

This study is testing a new genetic screening program for newborns in China to see if it can help identify serious hereditary diseases early and improve their chances of survival.

Quick facts

Study typeObservational
AgesAny age to 100 Days
SexAll
Enrollment4000 (estimated)
SponsorChildren's Hospital of Fudan University
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJanuary 1, 2021
Main results expectedNovember 2025
Study endsDecember 2025
Registry record updatedFebruary 20, 2025
Trial IDNCT04905537 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study include newborns under 100 days old who have experienced perinatal death after 20 weeks of gestation and have available biological samples for genetic screening.

Probably not a fit

Patients who are older than 100 days, have perinatal deaths before 20 weeks of gestation, or lack access to biological samples will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a comprehensive program for early genetic screening of neonatal critical illnesses in China, focusing on hereditary diseases that contribute to neonatal mortality. Researchers will analyze genetic data from over 10,000 cases to identify the spectrum of genetic diseases affecting critically ill newborns. Utilizing advanced second-generation sequencing technology, a targeted gene panel of 300 genes will be developed for screening. The study will also implement an intelligent data analysis process that integrates clinical phenotypes with genetic information, collaborating with multiple hospitals for clinical validation of the findings.

Why it matters

Potential benefit: If successful, this approach could significantly reduce neonatal mortality and disability by enabling early diagnosis and targeted interventions for genetic conditions.

How similar studies have gone: Other studies have shown success with genetic screening approaches in neonatal care, indicating a promising avenue for improving outcomes in this population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Postnatal age less than 100 days;
* Perinatal death after 20 weeks of gestation (more than 500 g)
* Can be retained biological samples for genetic screening;
* Biological parent or guardian's informed consent.

Exclusion Criteria:

* Reluctance of parents to use genetic sequencing data for subsequent research;
* Parents under 18 years of age or incapacitated for decision-making;
* subjects older than 100 days;
* Perinatal death less than 20 weeks of gestation or weight less than 500 g;
* Inherited metabolic diseases with chromosomal abnormalities;
* Multiple pregnancies;
* Lack of access to biological samples from which DNA can be extracted;
* Failure to sign informed consent.

Where it's running

  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.